Big recovery moves when it hits the bottom trend line last two times, about to do the same a third time. Probably a coincidence, but both of the previous take downs were followed by some good news. It wouldn't be too surprising if someone out there knows something we don't and is trying to shake out weak hands to get cheap shares. Expecting this to be $90+ soon.
Rolling NDA submission for Rocilentinib will be completed by July/August and will serve as another positive catalyst. Although CLVS management has said on the record that they are planning to bring their drugs to market on their own, I still believe they are just playing hard to get for now to minimize rampant speculation and liability of forward-looking statements. Current market cap sits around $2.8B with peak sales potential of about $2B/year for Rocilentinib. This doesn't even fully take into account Rucaparib that will likely file its NDA in 1Q16 and will compete with already approved Lynparza by AstraZeneca (AZN) that has $3B/yr sales potential. A buyout offer of at least $6-10B will be difficult to refuse, and even without the offer, the company deserves a valuation of $160+ once Rocilentinib is approved.
Rolling NDA submission for Rocilentinib will be completed by July/August and will serve as another positive catalyst. Although CLVS management has said on the record that they are planning to bring their drugs to market on their own, I still believe they are just playing hard to get for now to minimize rampant speculation and liability of forward-looking statements. Current market cap sits around $2.8B with peak sales potential of about $2B/year for Rocilentinib. This doesn't even fully take into account Rucaparib that will likely file its NDA in 1Q16 and will compete with already approved Lynparza by AstraZeneca (AZN) that has $3B/yr sales potential. A buyout offer of at least $6-10B will be difficult to refuse, and even without the offer, the company deserves a valuation of $160+ once Rocilentinib is approved.